Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

181. Predicting major adverse events after cardiac surgery in children

Predicting major adverse events after cardiac surgery in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2009

182. Adverse events after outpatient colonoscopy in the medicare population.

Adverse events after outpatient colonoscopy in the medicare population. BACKGROUND: Although use of colonoscopy has increased substantially among elderly Medicare beneficiaries, no one has described colonoscopy-related adverse events in a representative sample of Medicare patients. OBJECTIVE: To determine risk for adverse events after outpatient colonoscopy in elderly patients. DESIGN: Population-based, matched cohort study. SETTING: Surveillance, Epidemiology, and End Results cancer registry (...) compared with matched beneficiaries who did not have colonoscopy. Logistic regression was used to estimate adjusted predictive risks for adverse events and to assess whether these events varied by age, comorbid conditions, or type of colonoscopy. RESULTS: Persons undergoing colonoscopy had a higher risk for adverse gastrointestinal events than their matched group. Rates of adverse events after colonoscopy increased with age. Patients having polypectomy had higher risk for all adverse events compared

Annals of Internal Medicine2009

183. Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: a cluster-randomized trial

Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: a cluster-randomized trial 19398689 2009 04 28 2009 05 19 2013 11 21 1538-3679 169 8 2009 Apr 27 Archives of internal medicine Arch. Intern. Med. Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: a cluster-randomized trial. 771-80 10.1001/archinternmed.2009.51 Medication reconciliation at transitions in care (...) is a national patient safety goal, but its effects on important patient outcomes require further evaluation. We sought to measure the impact of an information technology-based medication reconciliation intervention on medication discrepancies with potential for harm (potential adverse drug events [PADEs]). We performed a controlled trial, randomized by medical team, on general medical inpatient units at 2 academic hospitals from May to June 2006. We enrolled 322 patients admitted to 14 medical teams

EvidenceUpdates2009

184. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease

Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease 19398687 2009 04 28 2009 05 19 2016 10 19 1538-3679 169 8 2009 Apr 27 Archives of internal medicine Arch. Intern. Med. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. 757-63 10.1001/archinternmed.2009.59 Adverse drug events and medication errors are threats to quality care. Inpatient studies suggest that a pharmacist may (...) reduce these events, but outpatient studies have not been forthcoming. We conducted a pooled analysis of 2 randomized controlled trials to determine the effect of pharmacist intervention on adverse drug events and medication errors. We studied 800 outpatient cases of hypertension stratified into complicated (n = 535) and uncomplicated (n = 265). Patients in the complicated stratum had heart failure or other cardiovascular complication. Computer programs examined 1-year electronic record data

EvidenceUpdates2009

185. Usefulness of electrocardiographic and echocardiographic left ventricular hypertrophy to predict adverse events in patients with a first non-ST-elevation acute myocardial infarction

Usefulness of electrocardiographic and echocardiographic left ventricular hypertrophy to predict adverse events in patients with a first non-ST-elevation acute myocardial infarction 19195501 2009 02 06 2009 03 19 2009 02 06 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Usefulness of electrocardiographic and echocardiographic left ventricular hypertrophy to predict adverse events in patients with a first non-ST-elevation acute myocardial infarction. 455-60 (...) . Five to 8% had LVH using Sokolow-Lyon or Cornell (voltage or product) criteria on admission; 15%, using either electrocardiographic criteria; and 24%, using echocardiography. LVH predicted the occurrence of adverse events (death, reinfarction, or severe angina or heart failure), with the strongest association found for the Cornell product (50.0% vs 24.9% of patients meeting or not meeting this criterion had complications, respectively; p = 0.002). This association persisted after adjusting

EvidenceUpdates2009

186. Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events

Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Boudreau R, Cimon K, Cunningham J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Cimon K (...) , Cunningham J. Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions Most of the studies concluded that cognitive function was not affected by taking oxybutynin, tolterodine, or darifenacin. All of the studies were short-term which may not reflect the typical patient on these medications. Three FDA advisories have been issued which stated that there have been reports of cognitive

Health Technology Assessment (HTA) Database.2009

187. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ CRD summary This review concluded that occurrence of glucocorticoid-related adverse events depended largely on the disease (...) in the study population. The overall rate of adverse events was 150 per 100 patient-years. Statistical heterogeneity was not assessed, which made it difficult to assess whether an appropriate approach was used to pool the results. Given these methodological concerns, the conclusions may be not reliable. Authors' objectives To assess the adverse events of low to medium dose oral glucocorticoids in patients with chronic inflammatory diseases. Searching MEDLINE, EMBASE and CINAHL were searched for full

DARE.2009

188. The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review

The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review Chao LF, Zhang AL, Liu HE, Cheng MH, Lam HB, Lo SK CRD summary The review (...) found that acupoint stimulation reduced chemotherapy-related nausea and vomiting among breast cancer patients, but that there was insufficient good quality evidence about other treatment-related adverse events. Given weaknesses in the review (such as language bias and suboptimal reporting), and the small size and limited quality of the primary studies, the authors’ conclusions may not be reliable. Authors' objectives To evaluate the use of acupoint stimulation for managing adverse events related

DARE.2009

189. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology

Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, Croce LS, Masutti F, Tiribelli C CRD summary (...) The authors concluded that rimonabant at a dose of 20mg was associated with an increased risk of adverse events. This was generally a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To determine the side effects associated with rimonabant. Searching MEDLINE, EMBASE, the Cochrane Library and the Cochrane Hepato-Biliary Group Controlled Trials Register were searched from inception to May 2009. Search terms were reported. References of identified trials

DARE.2009

190. Serenoa repens (saw palmetto): a systematic review of adverse events

Serenoa repens (saw palmetto): a systematic review of adverse events Serenoa repens (saw palmetto): a systematic review of adverse events Serenoa repens (saw palmetto): a systematic review of adverse events Agbabiaka TB, Pittler MH, Wider B, Ernst E CRD summary The authors concluded that available data suggested that Serenoa repens (Saw Palmetto) was well tolerated by most users and was not associated with serious adverse events; there was no evidence of drug interactions. Overall (...) . Reporting schemes of Australia, Germany, USA (Food and Drug Administration) and UK were used to retrieve additional data. World Health Organisation was contacted. Twenty-four manufacturer/distributors of S. repens and four herbalist organisations were contacted. Study selection Inclusion criteria appeared to be any study or source of data about reports of adverse events in people treated with monopreparations of S. repens . Studies of combined preparations of S. repens were excluded. Data sources

DARE.2009

191. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis Johansson K, Neovius K, Desantis SM, Rossner S, Neovius M CRD summary This review concluded that there was heterogeneity between the drugs in risk (...) rates for drop-out due to adverse effects and underlying causes. The low number needed to harm for rimonabant was of concern. The conclusion reflected the results of the review and appears likely to be reliable. Authors' objectives To assess drop-out rates due to adverse effect in trials of patients using orlistat, sibutramine or rimonabant. The authors stated that rimonabant had not been licensed in USA and was recently withdrawn in in the European Union after European Medicine Agency concluded

DARE.2009

192. Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents

Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents Article Text Aetiology Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents Statistics from

Evidence-Based Mental Health2009

193. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis

Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JP, Villari P CRD summary H5N1 vaccine formulations including a low haemagglutinin (...) antigen dose and a non-aluminium adjuvant might be the best available option in the event of a avian H5N1 influenza pandemic. The review was well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To evaluate the ability to evoke an immune response (immunogenicity) and adverse event profile of avian influenza A H5N1 vaccines. Searching MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, the World Health Organization clinical

DARE.2009

194. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease

Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS CRD summary The review evaluated efficacy and adverse events for Lactobacilli compared with placebo (...) in maintenance therapy for Crohn disease and found that both Lactobacillus johnsonii and Lactobacillus rhamnosus strain GG (LGG) had no benefit for relapse; LGG significantly increased relapse, but only in children. The extent to which the conclusions are reliable is unclear due to the limited evidence available. Authors' objectives To evaluate the efficacy and adverse events of Lactobacilli compared with placebo in maintenance therapy for Crohn disease. Searching MEDLINE (from 1966 to June 2007), EMBASE

DARE.2009

195. Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children

Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children Green SM (...) , Roback MG, Krauss B, Brown L, McGlone RG, Agrawal D, McKee M, Weiss M, Pitetti RD, Hostetler MA, Wathen JE, Treston G, Garcia Pena BM, Gerber AC, Losek JD, Emergency Department Ketamine Meta-Analysis Study Group CRD summary This review concluded that patients sedated with ketamine were at higher risk of airway and respiratory adverse events if they were younger than 21 years, or if physicians used co-administered anticholinergics or benzodiazepines. The quality and variability of raw data

DARE.2009

196. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Leombruno JP, Einarson TR, Keystone EC CRD summary (...) The review evaluated anti-tumour necrosis factor treatment for rheumatoid arthritis and found that recommended doses did not increase the risk of death, serious adverse events, serious infection or malignancy. High dose anti-TNF therapy was associated with a twofold increase in the risk of serious infections. The review was well-conducted and the authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the safety of anti-tumour necrosis factor treatment for rheumatoid arthritis

DARE.2009

197. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during helicobacter pylori eradication therapy

Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during helicobacter pylori eradication therapy Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during helicobacter pylori eradication therapy Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during helicobacter pylori eradication therapy Zou J, Dong J, Yu XF CRD summary This well-conducted (...) review concluded that lactoferrin supplementation to Helicobacter pylori eradication regimens improved outcomes and was better tolerated. The author's conclusions are supported by the data presented. Authors' objectives To assess the effect of lactoferrin supplementation on the eradication rates and side effects during Helicobacter pylori eradication therapy. Searching EMBASE (1980 to October 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2008), PubMed (1966 to October 2008

DARE.2009

198. Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma

Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma Article Text Therapeutics Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma Statistics from Altmetric.com No Altmetric data available for this article. C J Cates Dr C J Cates, St George’s, University of London

Evidence-Based Medicine (Requires free registration)2009

199. Short term use of antipsychotics increases the risk of serious adverse events in elderly people with dementia

Short term use of antipsychotics increases the risk of serious adverse events in elderly people with dementia Short term use of antipsychotics increases the risk of serious adverse events in elderly people with dementia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Short term use of antipsychotics increases the risk of serious adverse events in elderly people with dementia Article Text Aetiology Short term use of antipsychotics increases the risk of serious adverse events in elderly people with dementia Statistics from Altmetric.com

Evidence-Based Mental Health2009